20 April 2021
Over the last twenty years, Fragment-based drug design (FBDD) has emerged as a prominent strategy. Yet FBDD is not without challenges, including commercial libraries often hampered by excessively sized fragments. Recently new assaying techniques have emerged that push the boundaries of what’s possible with fragment screening, offering collections specifically tailored to biophysical screening. In this webinar, two respected industry authorities reveal how next-generation FBDD fragment screening can assist biophysical researchers more efficiently identify and prioritize the best fragment hits, compress hit-to-lead campaign times, and reduce research cost and raise lead throughput.